 | For many years, the short-acting bronchodilator albuterol has been the primary fast-acting medicine for asthma attacks. However, many children who suffer from asthma — especially very young children ages 24 months to 5 years—have received overly high doses of adult full-strength albuterol,1 resulting in adverse drug events such as excitability, nervousness, and the inability to sleep.2
|
|
|
| Realizing that children have unique medical needs, Dey, L.P. developed the AccuNeb® brand to treat asthma in children as young as 24 months old. AccuNeb® Inhalation
Solution, which comes in premeasured unit-doses of quarter-strength (0.63 mg) and half-strength (1.25 mg) albuterol, is delivered using a nebulizer.3 Doctors prescribe these lower doses to relieve symptoms such as coughing, chest tightness, shortness of breath, and wheezing.1
|
|
|
|
 |
|
|
|
|
| AccuNeb® (albuterol sulfate) Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). |
 |
| Important Safety Information |
|
| In a clinical trial with AccuNeb® Inhalation Solution 0.63 mg, AccuNeb® Inhalation Solution 1.25 mg, and placebo, the most commonly reported adverse events were asthma exacerbations (11.1%, 13%, 8.5%), otitis media (0.9%, 4.3%, 0%), allergic reaction (3.4%, 0.9%, 1.7%), gastroenteritis (3.4%, 0.9%, 0.9%), and flu syndrome (2.6%, 2.6%, 1.7%). |
|
| Like other beta-adrenergic agonists, AccuNeb® Inhalation Solution can produce paradoxical bronchospasm, which may be life-threatening. AccuNeb® Inhalation Solution should be used with caution in patients with cardiovascular disorders and patients being treated with epinephrine, oral sympathomimetics, beta-blockers, MAOIs, or tricyclic antidepressants. |
|
| Please see Patient Prescribing Information. |
| |
|
|
|
